Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E23.26 EPS (ttm)1.41 Insider Own0.02% Shs Outstand6.17B Perf Week5.71%
Market Cap202.23B Forward P/E13.95 EPS next Y2.35 Insider Trans-7.05% Shs Float6.16B Perf Month4.53%
Income8.91B PEG5.60 EPS next Q0.50 Inst Own73.30% Short Float1.19% Perf Quarter-1.21%
Sales48.20B P/S4.20 EPS this Y-14.50% Inst Trans0.05% Short Ratio2.85 Perf Half Y-3.81%
Book/sh10.86 P/B3.02 EPS next Y12.28% ROA5.40% Target Price39.28 Perf Year16.23%
Cash/sh4.91 P/C6.68 EPS next 5Y4.15% ROE12.60% 52W Range26.61 - 36.18 Perf YTD7.91%
Dividend1.12 P/FCF31.61 EPS past 5Y3.10% ROI8.90% 52W High-9.36% Beta0.91
Dividend %3.42% Quick Ratio1.90 Sales past 5Y0.10% Gross Margin81.30% 52W Low23.25% ATR0.91
Employees78300 Current Ratio2.10 Sales Q/Q-50.90% Oper. Margin28.70% RSI (14)50.47 Volatility3.11% 2.65%
OptionableYes Debt/Eq0.53 EPS Q/Q-47.50% Profit Margin18.50% Rel Volume1.43 Prev Close33.48
ShortableYes LT Debt/Eq0.40 EarningsOct 27 BMO Payout75.50% Avg Volume25.83M Price32.79
Recom2.30 SMA201.05% SMA50-2.08% SMA200-1.80% Volume36,324,900 Change-2.06%
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Oct-06-15 05:27PM  PFIZER INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:11PM  Health care stocks take a broad beating as sector turns negative on the year at MarketWatch
12:03PM  Has Valeant Fallen Too Far? at
Oct-05-15 04:15PM  3 Stocks with Strong Competitive Positions at Motley Fool
03:17PM  Trans-Pacific Partnership May Face Tough Sledding In the House at Forbes
03:09PM  BMS paying $14.6M to settle SEC charges on payments in China
12:48PM  How Common Is It for Companies to Raise Drug Prices?
Oct-03-15 01:48AM  Buy Where Others Aren't Shopping at
Oct-02-15 05:14PM  Grade the upgrade: Pfizer, Google, Dunkin'
04:40PM  Merck KGaA's Pipeline on Track, Updates Key R&D Projects
03:30PM  Pfizer Raised Prices on 133 Drugs This Year, And It's Not Alone at Bloomberg
02:42PM  Stocks Climb as Crude Oil Jumps, Energy Rallies at TheStreet
01:33PM  Is Bad News Good News For Market? Stocks Rally After Weak Start at Investor's Business Daily
12:28PM  Why Morgan Stanley Downgraded Gilead, Valeant & Regeneron at
11:31AM  10-Year Yield Drops Below 2%
08:30AM  Pfizer Inc. Announces Final Results of Exchange Offers Business Wire
03:31AM  Novartis biosimilar copycat takes aim at Amgen's drug Enbrel Reuters
Oct-01-15 07:02PM  Technically talented lawyers are increasingly valued at Financial Times
04:38PM  Bristol-Myers' gets early approval of combo cancer treatment
04:00PM  Stocks close mixed ahead of big jobs Friday at CNBC
03:26PM  Massive, unexpected drug price increases are happening all the time
09:20AM  Corrected-Merck KGaA says avelumab alliance with Pfizer on track Reuters
09:20AM  Pfizer Raises 2015 Outlook on Hospira Acquisition, Shares Up
08:01AM  3 Biotechs That Play Well with Others at Motley Fool
08:00AM  Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline Business Wire
Sep-30-15 05:06PM  How Did Sanofi Pasteur Perform in 2Q15?
05:00PM  Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers Business Wire
04:23PM  Pfizer (PFE) Stock Closes Higher, Raises Full-Year Revenue, Earnings Forecasts at TheStreet
03:08PM  Johnson & Johnsons Pharmaceuticals Segment Grows in 2Q15
02:03PM  Dow down, not out
01:03PM  Pfizer Boosts Its Guidance, Suggesting Better Times May Be Coming at Motley Fool
09:41AM  Stocks to Watch: Tesla, Pfizer, Paychex, Campbell Soup at The Wall Street Journal
09:19AM  Pfizer Edges Outlook Higher to Factor in Hospira at The Wall Street Journal
09:02AM  Pfizer lifts FY adjusted profit forecast on Hospira buy
08:30AM  Pfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015 Business Wire
08:18AM  3 Reasons Pfizer Is the Strongest Big Pharma Play Now at TheStreet
08:00AM  Is 50 Really the New 30? Your Immune System May Not Think So Business Wire
Sep-29-15 10:05AM  Bristol-Myers Squibbs Cardiovascular Segment in 2Q15
09:42AM  Which Big Pharma Will Grab the Lions Share of the Cancer Immunotherapy Market? at Motley Fool
Sep-28-15 07:01PM  UK scientists start stem cell trial of potential blindness cure
05:33PM  What to buy on a biotech buying spree
04:31PM  US STOCKS-Wall St drops as anxious investors eye China Reuters
04:17PM  Workday Analyst Day Comes As Stock In A Funk at Investor's Business Daily
04:01PM  The 4 Stocks That Sank the DJIA on Monday at 24/7 Wall St.
04:01PM  Stocks Slump on Fed, China, and Biotech Worries at TheStreet
03:09PM  Sanofi settles lawsuit enabling rival to Lantus insulin
03:04PM  US STOCKS-Wall St drops as China data rattles investors
02:54PM  Stocks Sell Off in Volatile Trading Ahead of Jobs Friday at TheStreet
09:32AM  Dow falls 100 points in open; energy falls more than 1% at CNBC
Sep-25-15 06:02PM  Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer at TheStreet
03:22PM  Dow 30 Stock Roundup: Boeing Receives Orders Worth $38B From China Cos, Caterpillar to Cut 5K Jobs
02:32PM  Will Pfizer (PFE) Stock be Helped by New Quarterly Dividend? at TheStreet
01:39PM  VLUEs Holdings: 2015 Performance Breakdown
12:51PM  AbbVie Spurns Galapagos To Advance Own Arthritis Drug at Investor's Business Daily
10:10AM  Pfizer Declares 28-Cent Fourth-Quarter 2015 Dividend Business Wire
08:40AM  Short Sellers Boost Positions in Major Pharma at 24/7 Wall St.
07:00AM  Merck KGaA, Darmstadt, Germany, and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma Business Wire
07:00AM  Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma Business Wire
06:14AM  How fast money flowed in Pfizer
Sep-24-15 07:58PM  Stocks Recover From Lows in Final Hour of Trading at TheStreet
05:00PM  Merck KGaA, Darmstadt, Germany, and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab Business Wire
05:00PM  Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab Business Wire
04:30PM  Is the government supporting drug price hikes?
01:05PM  Pfizer to develop cancer drug partnered with Cambridge biotech Bind at
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference Business Wire
09:45AM  Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter at 24/7 Wall St.
06:47AM  Stock Buyback Binge Continues
06:46AM  3 Reasons a Company May Choose to Cut Its Dividend at Motley Fool
12:01AM  Pfizers Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection Business Wire
Sep-23-15 09:32PM  Why This China Drug Play Should Be in Your Portfolio at
01:21PM  Under HIllary Clinton, Generic Drugmakers Could Soar at Motley Fool
01:14PM  Amgen, Allergan Biosimilar Avastin Hits In Trial at Investor's Business Daily
10:10AM  Stock Market News for September 23, 2015
08:21AM  What Stocks Benefit From Hillary Clinton's Drug Pricing Plan? at Motley Fool
05:56AM  New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression CNW Group
05:27AM  New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression PR Newswire
Sep-22-15 06:37PM  Biotech stocks fall further as Hillary Clinton unveils drug policy at Financial Times
06:00PM  Pfizer's Xeljanz Tops Phase III Ulcerative Colitis Studies
05:25PM  Hillary's Attack On Drug Companies Will Hit An Unintended Target at Investor's Business Daily
05:00PM  Dried toad and snakeskin: Old-school remedies cool China's vitamin fever
04:51PM  Pfizer says it could be leader in cancer with many new drugs
03:01PM  Enactment Of Clinton Prescription Drug Plan Will Result In R&D Job Losses at Forbes
12:11PM  Biotech stocks exposed to Hillary's plan
11:35AM  XRpro Sciences Completes Name Change to Icagen, Inc. Following Acquisition of Pfizer Ion Channel Platform Assets PR Newswire
10:00AM  New Centrum® VitaMints® Offer a Refreshingly New Way to Take a Multivitamin Business Wire
09:50AM  10 Investment Predictions for 2030
07:04AM  Whats the Outlook for Eli Lilly?
Sep-21-15 07:01PM  Biotech stocks fall on Clinton vow to fight 'price gouging'
05:39PM  Apple tops stock-buyback list even as repurchases shrink at MarketWatch
05:39PM  Apple tops stock-buyback list even as repurchases shrink
05:33PM  Stocks end higher, led by financial shares; drugmakers drop
04:57PM  Stocks end higher, but health-care selloff caps gains at MarketWatch
04:36PM  What Drove Sanofis Growth in 2Q15?
03:32PM  Stocks gain, led by financial shares; drugmakers drop
02:16PM  Rally Flames Out as Health Care Sells Off at TheStreet
01:31PM  Stocks Turn Mixed as Rally Flames Out at TheStreet
12:24PM  Pfizer (PFE) Stock Climbs on Positive Phase 3 Test Results at TheStreet
08:45AM  These 7 Dow Stocks Set All-Time Highs In The Second Half Of 2015 As The Index Began Its Down Trend at Forbes
08:00AM  Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tofacitinib in Adults with Moderate-to-Severe Ulcerative Colitis Business Wire
06:01AM  The Cost of Sending the Wrong Message
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM